The State of Biomarkers in Product Development

Price range: $1,960.00 through $2,940.00

June 2010

Licensing Options

  • SINGLE-USER LICENSE

    A Single-User License allows access to an individual user.

  • ENTERPRISE-WIDE LICENSE

    An Enterprise-Wide License allows access to all employees and sites within an organization.

Ask us about our library subscription plans

Report Overview

Q2, 2010

This innovative report focuses on interviews with 44 biomarkers specialists from 37 different biopharma companies. Participants provide views to their biomarker strategies, experiences, and predictions for their adoption in drug development.

Specifically, the report details pharma companies’ current and future adoption of 6 different types of biomarkers including:

  • Diagnostic Biomarkers
  • Early Detection / Screening Biomarkers
  • Predictive Biomarkers
  • Prognostic Biomarkers
  • Surrogate Biomarkers
  • Toxicity Biomarkers

 

What you will learn:

 

  • Which CROs are viewed as having a credible biomarkers service offering
  • Current and future adoption of 6 different categories of biomarkers by drug developers
  • Barriers and drivers of biomarkers adoption
  • Sponsors’ outsourcing intentions for products with biomarkers and for biomarker development
  • At what stages in development companies typically develop their biomarkers strategies
  • Preferred Service Providers for Biomarkers
  • Most Credible Biomarker Providers
  • Service Provider Differentiation Ideas
  • Drivers for Biomarker Development

 

Report Contents:

 

  1. Maturing Service Identifies Benefits of Early Strategy
  2. Outsourcing Strategies
  3. Sponsor Drivers and Roadblocks
  4. Trends in Biomarker Types and Technologies

Questions?

Our team is here to help.

For questions about syndicated report purchases, custom research solutions, or other billing-related topics, please contact sales@ISRreports.com.

Related products